- HK$14.27bn
- HK$15.71bn
- CNY7.82bn
- 87
- 77
- 14
- 66
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.76 | ||
| PEG Ratio (f) | 0.36 | ||
| EPS Growth (f) | 22.91% | ||
| Dividend Yield (f) | 1.66% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | 1.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.69 | ||
| EV to EBITDA | 4.98 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.16% | ||
| Return on Equity | 11.49% | ||
| Operating Margin | 28.41% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 5,318.09 | 5,587.64 | 6,382.01 | 6,865.73 | 7,815.94 | 8,629.93 | 9,385.25 | 11.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -22 | -8.26 | +71.32 | +35.8 | -25.81 | +30.15 | +8.95 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.
Directors
- Jing Lou CHM (58)
- Zhenping Zhu PRE (56)
- Fei Wang CFO (44)
- Dongmei Su SVP (51)
- Yongfu Chen VPR (64)
- Weihong Xiao GMG (52)
- Yong Xu GMG (56)
- Kwok Fai Lee SEC
- Yanli Liu SEC (40)
- Bin Huang NED (60)
- Ke Tang NED (41)
- Joo Yeow Ng NID (57)
- Tianruo Pu NID (53)
- Hoi Ti Heidi Yang NID (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 9th, 2006
- Public Since
- June 11th, 2015
- No. of Employees
- 5,411
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited- Shares in Issue
- 2,398,562,724
- Address
- No. 3 A1, Road 10, SHENYANG, 110027
- Web
- https://www.3sbio.com/
- Phone
- +86 2425811820
- Auditors
- Ernst & Young CPA
Upcoming Events for 1530
Half Year 2024 3SBio Inc Earnings Release
Similar to 1530
3D Medicines
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Co
Stock Exchange of Hong Kong Limited
FAQ
What is the 3SBio share price?
As of Today at 19:00 UTC, shares in 3SBio are trading at HK$5.95. This share price information is delayed by 15 minutes.
How has the 3SBio share price performed this year?
Shares in 3SBio last closed at HK$5.95 and the price had moved by -27.08% over the past 365 days. In terms of relative price strength the 3SBio share price has underperformed the FTSE Developed Asia Pacific Index by -26.58% over the past year.
What are the analyst and broker recommendations for 3SBio?
The overall consensus recommendation for 3SBio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the 3SBio dividend yield?
3SBio does not currently pay a dividend.
Does 3SBio pay a dividend?
3SBio does not currently pay a dividend.
When does 3SBio next pay dividends?
3SBio does not currently pay a dividend.
How do I buy 3SBio shares?
To buy shares in 3SBio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 3SBio?
As of the previous close price of HK$5.95, shares in 3SBio had a market capitalisation of HK$14.27bn.
Where are 3SBio shares listed?
Here are the trading details for 3SBio:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1530
What kind of share is 3SBio?
Based on an overall assessment of its quality, value and momentum 3SBio is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 3SBio share price forecast for 2024?
The analyst consensus target price for shares in 3SBio is HK$7.48. That is 25.77% above the last closing price of HK$5.95.
Analysts covering 3SBio currently have a consensus Earnings Per Share (EPS) forecast of CNY0.79 for the next financial year.
What is the trend in the 3SBio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 3SBio. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -19.71%.
As of the last closing price of HK$5.95, shares in 3SBio were trading -10.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 3SBio PE Ratio?
The 3SBio PE ratio based on its reported earnings over the past 12 months is 6.76. The shares last closed at HK$5.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 3SBio?
3SBio's management team is headed by:
- Jing Lou - CHM
- Zhenping Zhu - PRE
- Fei Wang - CFO
- Dongmei Su - SVP
- Yongfu Chen - VPR
- Weihong Xiao - GMG
- Yong Xu - GMG
- Kwok Fai Lee - SEC
- Yanli Liu - SEC
- Bin Huang - NED
- Ke Tang - NED
- Joo Yeow Ng - NID
- Tianruo Pu - NID
- Hoi Ti Heidi Yang - NID